| Psoriasis vulgaris

Bimzelx vs Remicade

Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.

Deep comparison between: Bimzelx vs Remicade with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsRemicade has a higher rate of injection site reactions vs Bimzelx based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Remicade but not Bimzelx, including UnitedHealthcare

Category

Bimzelx

Remicade

At A Glance

RouteSC injection

FrequencyEvery 4-8 weeks

ClassIL-17A and F antagonist

RouteIV infusion

FrequencyEvery 8 weeks

ClassTNF-alpha inhibitor

Indications

Psoriasis vulgaris
Arthritis, Psoriatic
Non-Radiographic Axial Spondyloarthritis
Ankylosing spondylitis
Hidradenitis Suppurativa

Crohn Disease
Ulcerative Colitis
Rheumatoid Arthritis
Arthritis, Psoriatic
Psoriasis vulgaris

Dosing

Psoriasis vulgaris 320 mg SC at Weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter; for patients weighing 120 kg or more, consider 320 mg every 4 weeks after Week 16.

Arthritis, Psoriatic, Non-Radiographic Axial Spondyloarthritis, Ankylosing spondylitis 160 mg SC every 4 weeks; for Arthritis, Psoriatic with coexistent moderate to severe plaque psoriasis, use the plaque psoriasis dosing regimen.

Hidradenitis Suppurativa 320 mg SC at Weeks 0, 2, 4, 6, 8, 10, 12, 14, and 16, then every 4 weeks thereafter.

Crohn Disease, Ulcerative Colitis 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 8 weeks (adults and pediatric patients >= 6 years).

Rheumatoid Arthritis 3 mg/kg IV induction at 0, 2, and 6 weeks, then 3 mg/kg every 8 weeks in combination with methotrexate; dose may be increased up to 10 mg/kg every 8 weeks or every 4 weeks for incomplete responders.

Arthritis, Psoriatic, Psoriasis vulgaris 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 8 weeks.

Contraindications

—

Doses >5 mg/kg in patients with moderate or severe heart failure
Previous severe hypersensitivity reaction to infliximab, any inactive ingredient of REMICADE, or any murine proteins (including anaphylaxis, hypotension, and serum sickness)

Drug Interactions

833View drug interactions

1225View drug interactions

Adverse Reactions

Most common (>=1%) Upper respiratory infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, herpes simplex infections, acne, folliculitis, fatigue, diarrhea, urinary tract infection

Serious Suicidal ideation and behavior, serious infections, liver biochemical abnormalities, inflammatory bowel disease

Postmarketing Conjunctivitis, esophageal candidiasis

Most common (>10%) Infections (upper respiratory tract infection, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain.

Serious Pneumonia, cellulitis, abscess, sepsis, bacterial infection, hepatotoxicity, acute liver failure, malignancies (including lymphoma), pancytopenia, thrombocytopenia, leukopenia.

Postmarketing Neutropenia, agranulocytosis, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, peripheral demyelinating disorders, anaphylactic shock, cerebrovascular accidents, myocardial ischemia/infarction.

Pharmacology

Bimekizumab-bkzx is a humanized IgG1 monoclonal antibody that selectively binds IL-17A, IL-17F, and IL-17AF cytokines, inhibiting their interaction with the IL-17 receptor complex and suppressing the release of proinflammatory cytokines and chemokines.

TNF-alpha antagonist; infliximab is a chimeric IgG1 monoclonal antibody that neutralizes the biological activity of TNF-alpha by binding with high affinity to both soluble and transmembrane forms of TNF-alpha and inhibiting its binding to receptors, thereby reducing inflammation in RA, CD, UC, AS, PsA, and Ps.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Bimzelx